Skip to main content
Midas Edge

TriSalus Life Sciences, Inc.

For the period ended Sep 30, 2025. Filed Nov 13, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 13, 2025

TLSI$2.85-11.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Consolidated Statements of Stockholders’ Deficit

Nine months ended September 30, 2025 and 2024

(unaudited, in thousands, except share data)

Nine months ended September 30, 2025
Preferred stock · Common stock · Additional paid-in capital · Accumulated deficit · Total
Shares · Amount · Shares · Amount
Balance as of December 31, 20243,985,002$—31,279,264$3$253,652$(279,549)$(25,894)
Net loss—————(10,375)(10,375)
Exercise of options and vesting of restricted stock units——159,699—279—279
Issuance of common stock through employee stock purchase plan (2)——55,670—37—37
Stock-based compensation————1,583—1,583
Preferred stock conversion(365,000)—777,829————
Balance as of March 31, 20253,620,002—32,272,462$3$255,551$(289,924)$(34,370)
Net loss—————(8,288)(8,288)
Exercise of options and vesting of restricted stock units——155,051—56—56
Stock-based compensation (1)————2,517—2,517
Proceeds from sale of common stock——5,500,000—20,662—20,662
Preferred stock conversion(26,000)—55,746————
Balance as of June 30, 20253,594,002$—37,983,259$3$278,786$(298,212)$(19,423)
Net loss—————(10,811)(10,811)
Exercise of options and vesting of restricted stock units——45,042—88—88
Issuance of common stock through employee stock purchase plan (2)——49,939—50—50
Stock-based compensation————3,371—3,371
Preferred stock conversion(3,594,002)—11,813,059111,946(11,947)—
Balance as of September 30, 2025—$—49,891,299$4$294,241$(320,970)$(26,725)
(1) Amount reflects $0.6 million related to 2024 bonus paid in 2025 in the form of stock-based compensation.
(2) The Company records the issuance of the shares when they are recorded by the transfer agent and as such, there could be timing differences between when the expense is recorded and shares are transferred.
Nine months ended September 30, 2024
Preferred stock · Common stock · Additional paid-in capital · Accumulated deficit · Total
Shares · Amount · Shares · Amount
Balance as of December 31, 20234,015,002$—26,413,213$2$222,437$(249,504)$(27,065)
Net loss—————(13,206)$(13,206)
Exercise of options and vesting of restricted stock units (3)——(4,941)—7—$7
Stock-based compensation————1,086—$1,086
Proceeds from sale of common stock——350,000—3,141—$3,141
Balance as of March 31, 20244,015,002—26,758,272$2$226,671$(262,710)$(36,037)
Net loss—$————(4,332)(4,332)
Exercise of options and vesting of restricted stock units—$—1,191—5—5
Stock-based compensation————1,275—1,275
Proceeds from sale of common stock——400,000—3,602—3,602
Record exchange warrants————11,923—11,923
Record issuance costs————(1,699)—(1,699)
Balance as of June 30, 20244,015,002—27,159,463$2$241,777$(267,042)$(25,263)
Net loss—$————(2,399)(2,399)
Exercise of options and vesting of restricted stock units——660—2—2
Issuance of common stock through employee stock purchase plan (2)——49,939—278—278
Stock-based compensation————1,300—1,300
Proceeds from sale of common stock——1,116,59115,647—5,648
Record exchange warrants——2,110,366————
Preferred stock conversion(30,000)—32,645————
Balance as of September 30, 20243,985,002$—30,469,664$3$249,004$(269,441)$(20,434)
(3) Amount reflects 2,906 shares issued for option exercises and 7,847 shares returned from options exercised in 2023 to correct clerical error.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.